Amarin Successfully Completes All Remaining Clinical Studies for AMR101 NDA
August 01, 2011 08:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced...
Amarin Completes All Non-Clinical Work for AMR101 NDA Submission
July 07, 2011 03:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the...
Amarin to Present at the Jefferies 2011 Global Healthcare Conference
June 01, 2011 07:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Announces Global Supply Network for AMR101
May 31, 2011 02:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, May 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the...
Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
May 19, 2011 08:54 ET | Amarin Corporation plc
NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today summarized additional MARINE...
Amarin-Sponsored Posters to be Presented Today at the National Lipid Association 2011 Annual Scientific Sessions
May 19, 2011 08:52 ET | Amarin Corporation plc
-EPA Therapy Demonstrates a Wide Range of Lipid Lowering Benefits Without the LDL-C Increase as Seen With Omega-3s Containing DHA- -Amarin's AMR101 Contains >96% EPA- NEW YORK, May 19,...